Ganciclovir

Specifications

82410-32-0CAS Number

627-054-3EC Number

2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)-1H-purin-6-oneIUPAC Name

C9H13N5O4Chemical Formula

255.23 g/molMolecular Weight

ganciclovir; 82410-32-0; Gancyclovir; Vitrasert; Zirgan; BW-759U; Ganciclovirum; RS-21592; BW 759U; Cymevene; Virgan; Cymevan; 2'-Nor-2'-deoxyguanosine; 9-((2-Hydroxy-1-(hydroxymethyl)ethoxy)methyl)guanine; 9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine; DTXSID8041032; P9G3CKZ4P5; 9-((1,3-Dihydroxy-2-propoxy)methyl)guanine; NSC-759656; 2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-6,9-dihydro-3H-purin-6-one; CHEBI:465284; 2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)-1H-purin-6-one; 2-(6-Amino-purin-9-ylmethoxy)-propane-1,3-diol; 2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-1H-purin-6(9H)-one; 6H-Purin-6-one, 2-amino-1,9-dihydro-9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)-; DTXCID6021032; 2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-9H-purin-6-ol; 2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)-3H-purin-6-one; 2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-3H-purin-6(9H)-one; 2-Amino-9-(2-hydroxy-1-hydroxymethyl-ethoxymethyl)-1,9-dihydro-purin-6-one; 2-amino-9-(2-hydroxy-1-hydroxymethylethoxymethyl)-6,9-dihydro-1H-6-purinone; 9-[[2-Hydroxy-1-(hydroxymethyl)ethoxy]methyl]guanine; Nordeoxyguanosine; NSC716361; Ganzyk-rtu; 2-amino-9-(((1,3-dihydroxypropan-2-yl)oxy)methyl)-6,9-dihydro-3H-purin-6-one; RefChem:922069; 2'NDG; Ganciclovir, Monosodium Salt; J05AB06; S01AD09; 2-Amino-1,9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)-6H-purin-6-one; Cytovene; Hydroxyacyclovir; 2-Amino-9-(((1,3-dihydroxypropan-2-yl)oxy)methyl)-1H-purin-6(9H)-one; C9H13N5O4; 2'-NDG; MFCD00870588; Natclovir; 9-(1,3-DIHYDROXY-PROPOXYMETHANE)GUANINE; GA2; 2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-1,9-dihydro-6H-purin-6-one; MLS000028481; Guanine, 9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)-; s1878; NCGC00015471-02; HHEMG; SMR000058324; Biolf 62; Ganciclovirum [Latin]; CAS-82410-32-0; 2-amino-9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]-3H-purin-6-one; 2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-6,9-dihydro-1H-purin-6-one; GCV; Citovirax; Cymeven; BW-B 759U; DRG-0018; 2-Amino-9-(((1,3-dihydroxypropan-2-yl)oxy)methyl)-6,9-dihydro-1H-purin-6-one; Vitrasert (TN); Cytovene (TN); CCRIS 9212; HSDB 6512; SR-01000075894; GCV & MSL; UNII-P9G3CKZ4P5; Ganciclovir (JAN/USP/INN); 2-((2-amino-6-hydroxy-9H-purin-9-yl)methoxy)propane-1,3-diol; 2-[(2-amino-6-hydroxy-9H-purin-9-yl)methoxy]propane-1,3-diol; Ganciclovir CRS; 2-amino-9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]-1H-purin-6-one; 2-amino-9-(((1,3-dihydroxypropan-2-yl)oxy)methyl)-1,9-dihydro-6H-purin-6-one; 2-Amino-1,9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)-6-H-purin-6-one; BW-795; MB3795; Prestwick_1068; ST-605; Zirgan (TN); GCV & 1110U81; Ganciclovir [USAN:USP:INN:BAN:JAN]; Ganciclovir (Standard); Opera_ID_284; GANCICLOVIR [MI]; Prestwick0_000839; Prestwick1_000839; Prestwick2_000839; Prestwick3_000839; GANCICLOVIR [INN]; GANCICLOVIR [JAN]; Lopac-G-2536; BIOLF62; Ganciclovir (BW 759); GANCICLOVIR [HSDB]; GANCICLOVIR [USAN]; CHEMBL182; EC 627-054-3; G 2536; GANCICLOVIR [VANDF]; SCHEMBL3033; SCHEMBL3034; 2-Amino-1,9-dihydro-9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]-6H-purin-6-one; GANCICLOVIR [MART.]; Lopac0_000539; 2'-Nor-2'-deoxyguanosine;; BSPBio_000797; GANCICLOVIR [USP-RS]; GANCICLOVIR [WHO-DD]; MLS001077349; BIDD:GT0783; SPBio_002718; GANCICLOVIR [EMA EPAR]; BPBio1_000877; orb1223934; orb1310384; Ganciclovir - Bio-X trade mark; SCHEMBL14491348; BDBM85707; GANCICLOVIR [EP IMPURITY]; GANCICLOVIR [ORANGE BOOK]; IRSCQMHQWWYFCW-UHFFFAOYSA-N; 2-[(2-amino-6-hydroxypurin-9-yl)methoxy]propane-1,3-diol; GANCICLOVIR [EP MONOGRAPH]; GLXC-07993; HMS1570H19; HMS2090K08; HMS2097H19; HMS2235C21; HMS3259B13; HMS3261L19; HMS3371H01; HMS3604L19; HMS3655M18; HMS3714H19; HMS5080O17; Pharmakon1600-01502362; GANCICLOVIR [USP MONOGRAPH]; MSK10028; NSC_3454; Tox21_110160; Tox21_500539; 2-(2-Amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol; BBL029078; BDBM50237614; EBC-07889; EBC-13406; HY-13637R; NSC759656; PDSP1_000816; PDSP2_000803; SBB066292; STK801910; STL514515; AKOS004119898; AKOS026749928; AKOS037492029; Tox21_110160_1; Valganciclovir hydrochloride impurity a; AC-8069; CCG-204629; CS-2014; DB01004; FG16550; Ganciclovir, >=99% (HPLC), powder; KS-1065; LP00539; NC00647; NSC 759656; SDCCGSBI-0050522.P002; SMP2_000038; NCGC00015471-01; NCGC00015471-03; NCGC00015471-04; NCGC00015471-05; NCGC00015471-06; NCGC00015471-08; NCGC00015471-16; NCGC00093928-01; NCGC00093928-02; NCGC00168567-01; NCGC00188980-01; NCGC00261224-01; 9-(1,3-dihydroxy-2propoxymethyl)guanine; BG164496; HY-13637; SY027981; 9-(1,3-dihydroxy-2-propoxymethyl)guanine; CAS_82410-32-0; 9-(1,3-dihydroxy-2-propoxymethyl)-guanine; 9-(1,3-Dihydroxy-2-propoxymethyl)guanine;; EU-0100539; G0315; NS00003516; SW197135-3; T0688; EN300-49857; C07019; D00333; Ganciclovir 100 |Ig/mL in Acetonitrile:Water; Ganciclovir 100 microg/mL in Acetonitrile:Water; 9-[[(1,3-Dihydroxy-2-propyl)oxy]methyl]guanine; F212141; Ganciclovir, Antibiotic for Culture Media Use Only; Q417640; SR-01000721941; Q-201148; SR-01000075894-1; SR-01000075894-4; SR-01000721941-3; BRD-K22662435-001-17-5; BRD-K22662435-001-18-3; BRD-K22662435-001-19-1; Z594284200; Ganciclovir, European Pharmacopoeia (EP) Reference Standard; VALGANCICLOVIR HYDROCHLORIDE IMPURITY A [USP IMPURITY]; Ganciclovir, United States Pharmacopeia (USP) Reference Standard; 2-Amino-1,9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]6H-purin-6-one; 2-amino-9-{[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl}hydropurin-6-one; Ganciclovir, Pharmaceutical Secondary Standard; Certified Reference Material; 2-amino-9-{[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl}-1,9-dihydro-6H-purin-6-one; Ganciclovir, 1.0 mg/mL (1% 1M HCl in Methanol), certified reference material; Guanine, 9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)- and MSL, neutralizing monoclonal antibodySynonyms